Pfizer is preparing for a market for obesity drugs on par with the booming business created by erectile dysfunction drug ...
A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase ...
An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a ...
Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 ...
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH ...
Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...
Eli Lilly stock prepares €15B Abivax acquisition as tirzepatide revenue hits $24.8B. Orforglipron oral weight loss drug ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
Moneta Funded introduces four distinct challenge formats, including Instant Funding, One-Step, Two-Step, and the unique ...
Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback